Filing Alert: Karyopharm Therapeutics Chapter 11
Karyopharm Therapeutics Inc., a Newton, MA-based commercial-stage pharmaceutical company pioneering novel cancer therapies, filed for Chapter 11 protection o...
Karyopharm Therapeutics Inc. and its debtor affiliate⁽¹⁾, a Newton, MA-based commercial-stage pharmaceutical company pioneering novel cancer therapies, filed for Chapter 11 protection on Nov. 2 in the U.S. Bankruptcy Court for the Southern District of Texas.
The company reports $111.3 million in assets and $441.5 million in liabilities. The filing indicates that there will be funds available for distribution to unsecured creditors. The case number is 26-90827.
⁽¹⁾ KPT Texas LLC.
Top Unsecured Claims
Key Parties
Counsel:
- Maegan Quejada
Sidley Austin LLP
Email: mquejada@sidley.com
Financial Advisor:
- FTI Consulting, Inc.
Investment Banker:
- Centerview Partners LLC
Signatories:
- Lori Macomber – Chief Financial Officer
Claims Agent:
- Stretto Inc.
Equity Security Holders:
- RA Capital Management LP – 8.45% Equity Interest
- Adage Capital Management LP – 6.71% Equity Interest
- Acorn Bioventures – 6.69% Equity Interest
- BlackRock Inc. – 6.26% Equity Interest
- Goldman Sachs Group Inc. – 6.12% Equity Interest
- Millennium Management LLC – 5.72% Equity Interest